patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_508456 | REC_0011101 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14 | 64 | female | 0 | 25 | 4.9 | 2 | entrectinib 600 mg daily | 28.7 | true | MSI-H | 2026-03-15T05:35:59.635480+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_186210 | REC_0011102 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 30 | 7.1 | 56 | male | 0 | 49 | 6.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 15.1 | true | MSS | 2026-03-15T05:35:59.635711+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_274863 | REC_0011103 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 10 | 11.5 | 56 | male | 0 | 15 | 6.5 | 6 | alectinib 600 mg BID | 11 | true | MSS | 2026-03-15T05:35:59.635998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_967267 | REC_0011104 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 27 | 11 | 62 | female | 1 | 12 | 5.6 | 6 | sotorasib 960 mg daily | 7.6 | false | MSI-H | 2026-03-15T05:35:59.636363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847865 | REC_0011105 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 30 | 16.6 | 57 | male | 0 | 6 | 6 | 5 | alectinib 600 mg BID | 11.2 | false | MSS | 2026-03-15T05:35:59.636620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_980052 | REC_0011106 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 15.1 | 69 | male | 0 | 14 | 4.9 | 6 | sotorasib 960 mg daily | 6.5 | false | MSI-H | 2026-03-15T05:35:59.637004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_823932 | REC_0011107 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 22 | 12.5 | 70 | female | 2 | 12 | 4.4 | 5 | entrectinib 600 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:59.637291+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_900237 | REC_0011108 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 25 | 8.5 | 60 | male | 1 | 35 | 4.6 | 1 | pembrolizumab 200 mg q3w | 6.4 | true | MSS | 2026-03-15T05:35:59.637556+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_208013 | REC_0011109 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 15.9 | 67 | female | 0 | 16 | 4.3 | 5 | alectinib 600 mg BID | 11.3 | true | MSS | 2026-03-15T05:35:59.637818+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460407 | REC_0011110 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 15 | 73 | female | 1 | 8 | 3.3 | 6 | alectinib 600 mg BID | 16.2 | false | MSS | 2026-03-15T05:35:59.638067+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_542358 | REC_0011111 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 31 | 23 | 78 | female | 3 | 19 | 3.8 | 2 | entrectinib 600 mg daily | 13.3 | false | MSS | 2026-03-15T05:35:59.638318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_847110 | REC_0011112 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 6.8 | 71 | female | 2 | 27 | 7 | 5 | sotorasib 960 mg daily | 17.5 | true | MSS | 2026-03-15T05:35:59.638564+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_201151 | REC_0011113 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 26 | 5 | 64 | female | 0 | 45 | 8 | 4 | pembrolizumab 200 mg q3w | 9 | false | MSS | 2026-03-15T05:35:59.638819+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_852386 | REC_0011114 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.1 | 81 | female | 2 | 14 | 4.1 | 2 | sotorasib 960 mg daily | 8.6 | false | MSS | 2026-03-15T05:35:59.639069+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_615271 | REC_0011115 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 24 | 15.9 | 81 | male | 2 | 5 | 6.2 | 3 | osimertinib 80 mg daily | 6.2 | false | MSI-H | 2026-03-15T05:35:59.639327+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_991044 | REC_0011116 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 8.9 | 52 | male | 0 | 12 | 5.8 | 4 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.639712+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_811595 | REC_0011117 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 19 | 14.8 | 65 | female | 0 | 21 | 5.4 | 5 | osimertinib 80 mg daily | 5.8 | true | MSI-H | 2026-03-15T05:35:59.639984+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_444165 | REC_0011118 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 4.2 | 76 | female | 2 | 26 | 5 | 6 | carboplatin + paclitaxel + pembrolizumab | 14.2 | true | MSS | 2026-03-15T05:35:59.640477+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637812 | REC_0011119 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 12.1 | 63 | male | 1 | 21 | 5 | 8 | pembrolizumab 200 mg q3w | 7.2 | false | MSS | 2026-03-15T05:35:59.640800+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_785891 | REC_0011120 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9 | 73 | male | 1 | 9 | 5.8 | 7 | sotorasib 960 mg daily | 18.6 | false | MSS | 2026-03-15T05:35:59.641050+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_670456 | REC_0011121 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 19 | 10.5 | 76 | female | 1 | 14 | 5.5 | 1 | alectinib 600 mg BID | 18.4 | false | MSI-H | 2026-03-15T05:35:59.641285+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_467876 | REC_0011122 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 30 | 12.8 | 71 | female | 1 | 14 | 6.4 | 2 | osimertinib 80 mg daily | 17.1 | false | MSI-H | 2026-03-15T05:35:59.641523+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_184534 | REC_0011123 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 11.5 | 62 | male | 1 | 16 | 5.8 | 4 | osimertinib 80 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:35:59.641760+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_691091 | REC_0011124 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 15.2 | 69 | male | 0 | 14 | 4.8 | 5 | entrectinib 600 mg daily | 8.9 | true | MSS | 2026-03-15T05:35:59.641998+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_259951 | REC_0011125 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 10.3 | 78 | male | 3 | 12 | 3.9 | 4 | osimertinib 80 mg daily | 12.6 | false | MSS | 2026-03-15T05:35:59.642245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_130873 | REC_0011126 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 11 | 61 | female | 0 | 26 | 4.6 | 1 | entrectinib 600 mg daily | 22 | false | MSI-H | 2026-03-15T05:35:59.642498+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_681442 | REC_0011127 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 17 | 13.5 | 81 | female | 1 | 21 | 5.5 | 1 | osimertinib 80 mg daily | 5.9 | true | MSI-H | 2026-03-15T05:35:59.642738+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_153434 | REC_0011128 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 7.6 | 57 | female | 1 | 14 | 7.7 | 6 | osimertinib 80 mg daily | 19.1 | false | MSS | 2026-03-15T05:35:59.642973+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_561061 | REC_0011129 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 31 | 14.4 | 69 | female | 0 | 6 | 6.8 | 5 | pembrolizumab 200 mg q3w | 11.4 | true | MSI-H | 2026-03-15T05:35:59.643316+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_573529 | REC_0011130 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.5 | 80 | female | 1 | 68 | 3.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 8.1 | false | MSS | 2026-03-15T05:35:59.643549+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_452663 | REC_0011131 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 11.7 | 60 | male | 1 | 16 | 6.2 | 7 | osimertinib 80 mg daily | 17.1 | false | MSS | 2026-03-15T05:35:59.643789+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_401598 | REC_0011132 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None (PD-L1 high) | 30 | 8 | 74 | female | 3 | 53 | 6 | 1 | pembrolizumab 200 mg q3w | 16.6 | false | MSS | 2026-03-15T05:35:59.644021+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_203534 | REC_0011133 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 27 | 10.4 | 55 | male | 1 | 10 | 6.3 | 2 | alectinib 600 mg BID | 20.3 | false | MSI-H | 2026-03-15T05:35:59.644372+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_817858 | REC_0011134 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 27 | 15.1 | 63 | female | 0 | 24 | 5.9 | 10 | alectinib 600 mg BID | 15.2 | true | MSI-H | 2026-03-15T05:35:59.644624+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_125319 | REC_0011135 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 31 | 5.6 | 71 | female | 1 | 13 | 4.3 | 6 | sotorasib 960 mg daily | 14.8 | true | MSS | 2026-03-15T05:35:59.644876+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_831692 | REC_0011136 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 13.9 | 63 | female | 1 | 13 | 4.4 | 8 | alectinib 600 mg BID | 4.9 | true | MSI-H | 2026-03-15T05:35:59.645144+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777925 | REC_0011137 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 22 | 6.8 | 67 | male | 0 | 13 | 4.9 | 9 | pembrolizumab 200 mg q3w | 15.5 | false | MSS | 2026-03-15T05:35:59.645474+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_478892 | REC_0011138 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 25 | 2.8 | 67 | female | 0 | 28 | 6.9 | 1 | carboplatin + paclitaxel + pembrolizumab | 18.1 | false | MSS | 2026-03-15T05:35:59.645720+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_487538 | REC_0011139 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 5.7 | 67 | female | 1 | 5 | 5.6 | 5 | pembrolizumab 200 mg q3w | 7.8 | false | MSS | 2026-03-15T05:35:59.645966+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489447 | REC_0011140 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 22 | 12.1 | 58 | female | 0 | 17 | 2.9 | 2 | osimertinib 80 mg daily | 15.3 | false | MSS | 2026-03-15T05:35:59.646214+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647066 | REC_0011141 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 14.7 | 64 | female | 0 | 16 | 4.4 | 5 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:59.646475+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_694173 | REC_0011142 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 18 | 7.4 | 74 | female | 2 | 65 | 7 | 6 | carboplatin + paclitaxel + pembrolizumab | 11.8 | true | MSS | 2026-03-15T05:35:59.646851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_546452 | REC_0011143 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 23 | 8.9 | 72 | female | 2 | 14 | 6.2 | 1 | alectinib 600 mg BID | 8.2 | false | MSS | 2026-03-15T05:35:59.647102+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_451409 | REC_0011144 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 8.6 | 67 | female | 0 | 63 | 6.1 | 2 | carboplatin + paclitaxel + pembrolizumab | 10.5 | false | MSS | 2026-03-15T05:35:59.647344+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_623461 | REC_0011145 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 10 | 57 | male | 0 | 11 | 4.9 | 6 | alectinib 600 mg BID | 9.4 | false | MSS | 2026-03-15T05:35:59.647590+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_190832 | REC_0011146 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 25 | 6.2 | 71 | female | 0 | 15 | 4.6 | 4 | pembrolizumab 200 mg q3w | 10.9 | true | MSS | 2026-03-15T05:35:59.647829+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_963836 | REC_0011147 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 7.8 | 60 | female | 1 | 6 | 4.4 | 5 | pembrolizumab 200 mg q3w | 15.3 | false | MSS | 2026-03-15T05:35:59.648122+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818683 | REC_0011148 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 13.1 | 67 | female | 0 | 15 | 4.6 | 6 | osimertinib 80 mg daily | 5.9 | true | MSS | 2026-03-15T05:35:59.648396+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_613392 | REC_0011149 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 22 | 14.8 | 71 | female | 2 | 8 | 4.7 | 2 | entrectinib 600 mg daily | 31.8 | false | MSI-H | 2026-03-15T05:35:59.648651+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_331227 | REC_0011150 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 31 | 5.5 | 70 | female | 1 | 18 | 7.6 | 5 | osimertinib 80 mg daily | 9.8 | false | MSS | 2026-03-15T05:35:59.648903+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_368198 | REC_0011151 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 25 | 14 | 84 | female | 2 | 12 | 6.3 | 2 | sotorasib 960 mg daily | 18.5 | true | MSI-H | 2026-03-15T05:35:59.649146+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_198760 | REC_0011152 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 16.7 | 63 | female | 1 | 22 | 5 | 3 | sotorasib 960 mg daily | 10.3 | true | MSS | 2026-03-15T05:35:59.649387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_574291 | REC_0011153 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 30 | 5.7 | 82 | female | 1 | 61 | 4 | 2 | carboplatin + paclitaxel + pembrolizumab | 11.1 | false | MSS | 2026-03-15T05:35:59.649636+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_725822 | REC_0011154 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 11.4 | 85 | female | 2 | 20 | 4.1 | 2 | osimertinib 80 mg daily | 14.9 | false | MSI-H | 2026-03-15T05:35:59.649887+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380578 | REC_0011155 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 20 | 13.7 | 55 | female | 0 | 14 | 4.2 | 7 | sotorasib 960 mg daily | 8.6 | false | MSI-H | 2026-03-15T05:35:59.650261+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_679563 | REC_0011156 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 7.2 | 78 | male | 2 | 83 | 4.9 | 7 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:59.650521+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_238601 | REC_0011157 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 18 | 14.6 | 62 | female | 0 | 24 | 5.8 | 5 | sotorasib 960 mg daily | 9.6 | false | MSI-H | 2026-03-15T05:35:59.650787+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135282 | REC_0011158 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 21 | 4.2 | 62 | female | 0 | 67 | 7.6 | 0 | pembrolizumab 200 mg q3w | 33.6 | true | MSS | 2026-03-15T05:35:59.651058+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_428443 | REC_0011159 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 34 | 11.4 | 69 | female | 1 | 2 | 5.7 | 6 | sotorasib 960 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:59.651337+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_243900 | REC_0011160 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 12 | 79 | female | 1 | 19 | 6.3 | 6 | sotorasib 960 mg daily | 14.4 | false | MSI-H | 2026-03-15T05:35:59.651598+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_700385 | REC_0011161 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 6.1 | 79 | female | 2 | 37 | 3.4 | 8 | carboplatin + paclitaxel + pembrolizumab | 13.4 | true | MSS | 2026-03-15T05:35:59.651850+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_793398 | REC_0011162 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 28 | 6.1 | 66 | female | 1 | 24 | 3.8 | 2 | carboplatin + paclitaxel + pembrolizumab | 18.6 | false | MSS | 2026-03-15T05:35:59.652150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_808115 | REC_0011163 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 6.3 | 72 | female | 2 | 47 | 4.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 22.5 | false | MSS | 2026-03-15T05:35:59.652422+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_275776 | REC_0011164 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 14.3 | 71 | female | 1 | 18 | 6.8 | 5 | pembrolizumab 200 mg q3w | 8.5 | false | MSS | 2026-03-15T05:35:59.652686+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693118 | REC_0011165 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 32 | 10.9 | 76 | female | 1 | 25 | 3.6 | 1 | alectinib 600 mg BID | 19.1 | true | MSI-H | 2026-03-15T05:35:59.652942+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_650264 | REC_0011166 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 7.1 | 68 | female | 0 | 3 | 4.9 | 5 | carboplatin + paclitaxel + pembrolizumab | 4.3 | false | MSS | 2026-03-15T05:35:59.653183+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_207819 | REC_0011167 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 29 | 7.6 | 61 | female | 0 | 36 | 5.3 | 6 | carboplatin + paclitaxel + pembrolizumab | 10 | false | MSS | 2026-03-15T05:35:59.653430+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_845598 | REC_0011168 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 23 | 5.3 | 58 | male | 1 | 28 | 6.7 | 5 | carboplatin + paclitaxel + pembrolizumab | 6.6 | true | MSS | 2026-03-15T05:35:59.653823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165486 | REC_0011169 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 23 | 3.5 | 74 | female | 1 | 22 | 6.3 | 1 | carboplatin + paclitaxel + pembrolizumab | 17 | true | MSS | 2026-03-15T05:35:59.654117+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_755788 | REC_0011170 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 27 | 12.3 | 53 | male | 0 | 12 | 7.6 | 10 | osimertinib 80 mg daily | 10.1 | true | MSS | 2026-03-15T05:35:59.654392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_224241 | REC_0011171 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 24 | 6.6 | 60 | female | 0 | 33 | 6.7 | 7 | pembrolizumab 200 mg q3w | 16.3 | true | MSS | 2026-03-15T05:35:59.654641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_661143 | REC_0011172 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 16.7 | 60 | male | 1 | 15 | 7.5 | 8 | osimertinib 80 mg daily | 12.4 | true | MSI-H | 2026-03-15T05:35:59.654889+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_104364 | REC_0011173 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 20 | 8.9 | 64 | male | 1 | 14 | 5.5 | 1 | sotorasib 960 mg daily | 16.6 | false | MSS | 2026-03-15T05:35:59.655135+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_932845 | REC_0011174 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 25 | 14.9 | 70 | female | 3 | 10 | 5.1 | 5 | entrectinib 600 mg daily | 14.5 | false | MSI-H | 2026-03-15T05:35:59.655392+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_600941 | REC_0011175 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 12.5 | 71 | female | 1 | 24 | 8 | 7 | alectinib 600 mg BID | 16 | false | MSS | 2026-03-15T05:35:59.655643+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_543417 | REC_0011176 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 27 | 8.2 | 68 | male | 1 | 10 | 4.5 | 8 | pembrolizumab 200 mg q3w | 5.8 | false | MSS | 2026-03-15T05:35:59.655895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_916128 | REC_0011177 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 20 | 11.6 | 63 | female | 1 | 21 | 6 | 7 | pembrolizumab 200 mg q3w | 16.8 | true | MSS | 2026-03-15T05:35:59.656279+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544090 | REC_0011178 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 23 | 10.9 | 51 | female | 0 | 23 | 7 | 2 | osimertinib 80 mg daily | 19.8 | false | MSI-H | 2026-03-15T05:35:59.656554+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321111 | REC_0011179 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 16.1 | 66 | female | 0 | 11 | 5.5 | 4 | osimertinib 80 mg daily | 6.6 | false | MSS | 2026-03-15T05:35:59.656823+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_123889 | REC_0011180 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 15 | 5.2 | 56 | male | 0 | 12 | 4.5 | 7 | pembrolizumab 200 mg q3w | 6.8 | true | MSS | 2026-03-15T05:35:59.657071+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764481 | REC_0011181 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 4 | 67 | female | 0 | 7 | 7 | 6 | osimertinib 80 mg daily | 4.4 | false | MSS | 2026-03-15T05:35:59.657444+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_105028 | REC_0011182 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 18 | 10.4 | 66 | female | 1 | 10 | 4.2 | 4 | entrectinib 600 mg daily | 8.5 | false | MSI-H | 2026-03-15T05:35:59.657702+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_794317 | REC_0011183 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 32 | 12.2 | 74 | female | 2 | 18 | 5 | 4 | entrectinib 600 mg daily | 14.3 | false | MSI-H | 2026-03-15T05:35:59.657952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_672786 | REC_0011184 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR exon 19 deletion | 21 | 10.8 | 67 | female | 1 | 19 | 5 | 0 | osimertinib 80 mg daily | 38.4 | false | MSS | 2026-03-15T05:35:59.658204+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_223582 | REC_0011185 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 31 | 8.1 | 61 | male | 0 | 20 | 6.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.6 | false | MSS | 2026-03-15T05:35:59.658470+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_739418 | REC_0011186 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 25 | 13.3 | 75 | female | 1 | 4 | 3.9 | 1 | entrectinib 600 mg daily | 22.4 | true | MSI-H | 2026-03-15T05:35:59.658740+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712005 | REC_0011187 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 16 | 17.8 | 74 | male | 1 | 5 | 5.8 | 4 | entrectinib 600 mg daily | 8.3 | false | MSI-H | 2026-03-15T05:35:59.658987+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_477893 | REC_0011188 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 30 | 7.5 | 77 | female | 0 | 18 | 4 | 1 | pembrolizumab 200 mg q3w | 18.1 | true | MSS | 2026-03-15T05:35:59.659216+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_293142 | REC_0011189 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 12.6 | 58 | female | 1 | 12 | 5.2 | 1 | sotorasib 960 mg daily | 21.9 | false | MSI-H | 2026-03-15T05:35:59.659464+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_824807 | REC_0011190 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 27 | 17.1 | 65 | male | 1 | 10 | 7.1 | 6 | osimertinib 80 mg daily | 17.5 | false | MSS | 2026-03-15T05:35:59.659714+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_465146 | REC_0011191 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 6.3 | 59 | female | 1 | 20 | 5.7 | 5 | pembrolizumab 200 mg q3w | 14.4 | false | MSS | 2026-03-15T05:35:59.659952+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_220599 | REC_0011192 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 23 | 8.8 | 66 | female | 0 | 14 | 5.8 | 4 | osimertinib 80 mg daily | 14.1 | true | MSS | 2026-03-15T05:35:59.660229+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_419141 | REC_0011193 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 30 | 15.5 | 62 | male | 1 | 22 | 5.8 | 5 | entrectinib 600 mg daily | 6.4 | false | MSS | 2026-03-15T05:35:59.660471+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_764201 | REC_0011194 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 16 | 5.4 | 71 | male | 1 | 29 | 4.8 | 3 | carboplatin + paclitaxel + pembrolizumab | 10.9 | false | MSS | 2026-03-15T05:35:59.660814+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_498141 | REC_0011195 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 33 | 11.3 | 58 | female | 1 | 12 | 4.2 | 5 | sotorasib 960 mg daily | 8.2 | false | MSS | 2026-03-15T05:35:59.661060+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_342108 | REC_0011196 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 23 | 12.7 | 71 | female | 2 | 17 | 5.9 | 2 | sotorasib 960 mg daily | 5.2 | false | MSS | 2026-03-15T05:35:59.661297+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_846241 | REC_0011197 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 28 | 15.4 | 68 | female | 1 | 27 | 5.9 | 5 | alectinib 600 mg BID | 13.3 | true | MSS | 2026-03-15T05:35:59.661531+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_124100 | REC_0011198 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 28 | 6.9 | 72 | female | 2 | 12 | 6.3 | 1 | osimertinib 80 mg daily | 20.7 | true | MSS | 2026-03-15T05:35:59.661764+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_855356 | REC_0011199 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 29 | 14 | 63 | male | 1 | 6 | 4.1 | 6 | sotorasib 960 mg daily | 10.7 | true | MSS | 2026-03-15T05:35:59.662002+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_560059 | REC_0011200 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 21 | 5.9 | 74 | female | 2 | 13 | 4.8 | 5 | sotorasib 960 mg daily | 16.4 | false | MSS | 2026-03-15T05:35:59.662228+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.